MedTrace Logo

Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients

NCT04799626 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-06-23

No results posted yet for this study

Summary

The investigator's purpose is to study the pharmacokinetics and pharmacodynamics of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc in elderly ICU patients and recommend an individual dosage regimen of those antibiotics.

Conditions

  • Elderly Infection

Interventions

DRUG

biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc

biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.

Sponsors & Collaborators

  • The Second Hospital of Shandong University

    collaborator OTHER

  • Shandong University

    lead OTHER

Principal Investigators

  • Wei Zhao, Ph.D · The Second Hospital of Shandong University

Eligibility

Min Age
65 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-03-30
Completion
2023-06-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04799626 on ClinicalTrials.gov